Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06040125 · ClinicalTrials.gov registry record · NA

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

A NA study of Prostate Cancer and Metastatic Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
3
Study locations

NCT06040125: Recruiting NA study of Prostate Cancer and Metastatic Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

NCT06040125 is a NA study of Prostate Cancer and Metastatic Prostate Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06040125, a NA study of Prostate Cancer and Metastatic Prostate Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). The names of the study intervention involved in this study is: • Supervised circuit training (aerobic and resistance exercise regimen)

Primary Outcome

Assessed by change in systemic inflammatory biomarkers through blood analysis (ul/ml).

Interventions

  • BEHAVIORAL Supervised Circuit Training

Study Locations (3)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-01-01
Est. Completion 2027-02-28
Phase NA
Dana-Farber Cancer Institute

781 total trials

What NCT06040125 shows while recruiting

NCT06040125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Supervised Circuit Training is the first listed.

NCT06040125 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06040125 about?

NCT06040125 is a clinical study titled "Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial". The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metast...

What is the current status of trial NCT06040125?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-01-01. Estimated completion is 2027-02-28.

What conditions does trial NCT06040125 study?

This clinical trial studies the following conditions: Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma.

What interventions are being tested in trial NCT06040125?

The interventions under investigation include: Supervised Circuit Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT06040125?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06040125 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06040125's enrollment target sits among peer trials

80 370th of 735 higher than 355 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06040125, the US trial registry maintained by the National Library of Medicine. NCT06040125 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.